|

Universal CD7-specific CAR gene-engineered T cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Shenzhen Geno-Immune Medical Institute1

Indications

  • NK-Cell Lymphoma1
  • T-Cell Acute Lymphoblastic Lymphoma1
  • T-cell Acute Lymphoblastic Leukemia1
  • Acute Myeloid Leukemia1
  • Cancer1

Other1 trial

Universal 4SCAR7U Targeting CD7-positive Malignancies
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.